Protara Therapeutics (TARA) Competitors $5.49 -0.29 (-5.02%) Closing price 04:00 PM EasternExtended Trading$5.60 +0.11 (+1.91%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARA vs. OLMA, AKBA, ORKA, TYRA, PVLA, TBPH, TERN, NRIX, GYRE, and ARVNShould you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Olema Pharmaceuticals (OLMA), Akebia Therapeutics (AKBA), Oruka Therapeutics (ORKA), Tyra Biosciences (TYRA), Palvella Therapeutics (PVLA), Theravance Biopharma (TBPH), Terns Pharmaceuticals (TERN), Nurix Therapeutics (NRIX), Gyre Therapeutics (GYRE), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry. Protara Therapeutics vs. Its Competitors Olema Pharmaceuticals Akebia Therapeutics Oruka Therapeutics Tyra Biosciences Palvella Therapeutics Theravance Biopharma Terns Pharmaceuticals Nurix Therapeutics Gyre Therapeutics Arvinas Protara Therapeutics (NASDAQ:TARA) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk. Do institutionals and insiders believe in TARA or OLMA? 38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 8.4% of Protara Therapeutics shares are owned by insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor TARA or OLMA? In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Protara Therapeutics. MarketBeat recorded 2 mentions for Olema Pharmaceuticals and 0 mentions for Protara Therapeutics. Olema Pharmaceuticals' average media sentiment score of 0.57 beat Protara Therapeutics' score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Protara Therapeutics Neutral Olema Pharmaceuticals Positive Which has better earnings and valuation, TARA or OLMA? Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtara TherapeuticsN/AN/A-$44.60M-$1.62-3.39Olema PharmaceuticalsN/AN/A-$129.47M-$1.98-4.73 Do analysts rate TARA or OLMA? Protara Therapeutics presently has a consensus target price of $19.60, indicating a potential upside of 257.01%. Olema Pharmaceuticals has a consensus target price of $23.33, indicating a potential upside of 149.29%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Protara Therapeutics is more favorable than Olema Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86Olema Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Which has more volatility & risk, TARA or OLMA? Protara Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Is TARA or OLMA more profitable? Protara Therapeutics' return on equity of -36.87% beat Olema Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Protara TherapeuticsN/A -36.87% -33.85% Olema Pharmaceuticals N/A -42.58%-38.65% SummaryProtara Therapeutics beats Olema Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARA vs. The Competition Export to ExcelMetricProtara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$223M$2.64B$6.11B$10.51BDividend YieldN/A57.79%5.73%4.81%P/E Ratio-3.3922.9984.5227.09Price / SalesN/A761.85609.45131.82Price / CashN/A168.7137.1661.22Price / Book1.155.3212.246.52Net Income-$44.60M$33.06M$3.32B$276.75M7 Day Performance5.17%-0.81%0.76%0.92%1 Month Performance81.19%9.20%8.03%4.20%1 Year Performance196.76%-3.82%71.13%37.86% Protara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARAProtara Therapeutics1.838 of 5 stars$5.49-5.0%$19.60+257.0%+210.8%$223MN/A-3.3930OLMAOlema Pharmaceuticals2.9862 of 5 stars$11.06-0.4%$24.00+117.0%-22.0%$761.84MN/A-5.5970Gap DownAKBAAkebia Therapeutics3.4349 of 5 stars$2.97+4.9%$6.75+127.3%+119.5%$750.36M$160.18M-17.47430ORKAOruka Therapeutics2.7887 of 5 stars$20.33+2.7%$42.00+106.6%-8.4%$741.15MN/A-7.23N/ATYRATyra Biosciences2.4771 of 5 stars$13.43-1.7%$31.86+137.2%-42.7%$728.04MN/A-7.5420High Trading VolumePVLAPalvella Therapeutics1.7344 of 5 stars$67.95+3.3%$69.27+1.9%N/A$727.51M$42.81M-5.62N/AShort Interest ↑TBPHTheravance Biopharma3.2343 of 5 stars$14.58+1.2%$23.00+57.8%+61.4%$725.70M$77.21M60.75110News CoverageGap UpTERNTerns Pharmaceuticals4.0791 of 5 stars$8.43+2.4%$15.49+83.7%+12.5%$720.22MN/A-8.1140News CoverageAnalyst ForecastNRIXNurix Therapeutics1.8622 of 5 stars$9.95+6.1%$29.07+192.2%-61.1%$717.09M$54.55M-3.81300Trending NewsAnalyst ForecastAnalyst RevisionGYREGyre Therapeutics1.2804 of 5 stars$7.34-0.9%$18.00+145.2%-37.5%$713.68M$105.76M734.7340News CoverageARVNArvinas3.5372 of 5 stars$9.62+0.1%$16.18+68.2%-65.2%$705.54M$263.40M-9.52420Analyst DowngradeGap Down Related Companies and Tools Related Companies OLMA Alternatives AKBA Alternatives ORKA Alternatives TYRA Alternatives PVLA Alternatives TBPH Alternatives TERN Alternatives NRIX Alternatives GYRE Alternatives ARVN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARA) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
